Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Available forms === Tazarotene is available in several topical formulations, including gels, creams, foams, and lotions, with concentrations ranging from 0.045% to 0.1%. Tazarotene was first approved in 1997 as a 0.05% and 0.1% gel, followed by 0.05% and 0.1% creams in 2000. In 2012, a 0.1% aerosol foam was introduced to provide easier application to hair-bearing or large surface areas of the skin. A 0.045% lotion was approved in 2019, which utilizes a polymeric emulsion technology to stabilize the active ingredient at a lower concentration with increased absorption. Tazarotene is also available as a fixed-dose combination drug in the topical formulation of halobetasol/tazarotene for use in psoriasis.
=== Announcement and development === We Happy Few was revealed on 26 February 2015, and publicly debuted at PAX East 2015, allowing attendees to go hands-on with a very early version of the project. During June 2015, Compulsion Games ran a successful Kickstarter campaign, raising US$266,163 of the target US$200,000 to fund the development of the game. About 2,000 of these supporters backed at levels to participate in the game's alpha-version testing alongside Compulsion's dedicated play-testing team of five, but Compulsion found this did not provide them enough feedback to know which way to take the narrative elements within the randomly generated world. Instead, Compulsion opted to open the game to an early access release in a playable state on various storefronts for Windows and on the Xbox One Xbox Game Preview program starting on 26 July 2016 as to be able to gain much more feedback. Part of their choice to use early access was to provide transparency of what the game was actually to be, wanting to avoid the pitfalls that happened with No Man's Sky on its release in August 2016. Compulsion found many were anticipating a AAA gaming experience from their small team, and thus wanted to make sure players were clear on what their goals were for We Happy Few. One issue faced during development in early access was managing the expectations of what We Happy Few was meant to be.
As mayor, Bukele began a "reordering" ("reordenamiento") to revitalize the city's historic downtown area and combat crime. On the day Bukele took office, he reverted the names of two streets in San Salvador (Calle Mayor Roberto D'Aubuisson and Boulevard Coronel José Arturo Castellanos) to Calle San Antonio Abad and Boulevard Venezuela, respectively. Both names had been changed by Bukele's predecessor, Norman Quijano. Zamora, who had become a member of San Salvador's municipal council, stated that the names were reverted due to flaws in the initial renaming process. He added that another street would be named in honor of Castellanos, who provided fake Salvadoran passports to 40,000 Central European Jews to help them escape the Holocaust. Bukele renamed 89 Avenida Norte in honor of Castellanos in June 2016. In December 2016, Bukele inaugurated the Cuscatlán Market to encourage street vendors to relocate their businesses. Many vendors refused to move, despite the market. Political opponents and investigative journalists accused him of negotiating with gangs to organize its construction, since it was located in gang-controlled territory. In January 2016, Bukele began a "San Salvador 100% Illuminated" campaign to "have a light on every corner of San Salvador" to combat crime in the city. The campaign was completed by May 2016. He also installed video-surveillance cameras in parts of San Salvador that were severely affected by crime. Bukele inaugurated the renovated downtown Gerardo Barrios Plaza in October 2017, and the new downtown Lineal Plaza in April 2018.
=== Isaac Kleiner === Dr. Isaac Kleiner (voiced by Harry S. Robins), a Black Mesa survivor, is one of the leading scientists in the human resistance to the Combine. His character design is based on the generic "nearly bald, glasses (Walter, as its model name suggests)" scientist model from the original Half-Life. Dr. Kleiner was one of Gordon Freeman's professors at MIT, recommending him for employment at Black Mesa to the Civilian Recruitment Division and working with him as part of the facility's Anomalous Materials team. He managed to survive the Resonance Cascade disaster of the first game with the aid of Eli Vance. In Half-Life 2, he operates an underground lab in an abandoned Northern Petrol building. A teleportation system, developed jointly by Kleiner and Eli Vance, connects to Vance's facility, several miles away. As a pet, Dr. Kleiner keeps a debeaked headcrab he calls 'Lamarr' (after the 1930s actress and inventor Hedy Lamarr). In Episode One, Kleiner appears on the video screens previously reserved for Dr. Breen's propaganda and instructs survivors to evacuate City 17, also encouraging them to procreate. He rallies people to prepare for the Combine's retaliation, stating that several new technologies developed during their occupation would be deployed as soon as possible to help fight the Combine. In Episode Two, Kleiner is working out of the White Forest Rocket Facility with Eli Vance and Arne Magnusson on a device intended to close the Combine Superportal created by the Citadel's destruction.
Sources: en.wikipedia.org
In December 2024, the Auditor General of Ontario questioned the financial prudence of the relocation. Contrary to the Ford government's business plan analysis, which projected $257 million in savings over 50 years, the AG found that relocation costs have already exceeded the anticipated savings, reaching approximately $400 million.In May 2025, the Canadian Architect magazine reported that draft versions of the structural engineering report by Rimkus Consulting that the Ontario government had relied on in deciding to close the centre, had originally recommended routine repairs and not closure, up until May 2024. This revelation was added to earlier reporting from Global News that Infrastructure Ontario had been in frequent communication with Rimkus in the leadup to the public release of the report in June 2024, and led the magazine to conclude that the language describing the consequences of not doing the routine repair that was later used to justify the closure had been inserted after political pressure. In February 2026, Ford unveiled the designs of the new building and announced that a contract had been awarded for its construction. It will cost an estimated $1 billion and will be smaller than the original facility, with a footprint of about 400,000 square feet. The Centre would also incorporate the Ontario Place pods as exhibit space and the Cinesphere. The proposed move has been controversial.
=== Risk factors === There are over 100 risk factors for pressure ulcers. Factors that may place a patient at risk include immobility, diabetes mellitus, peripheral vascular disease, malnutrition, cerebral vascular accident and hypotension. Other factors are age of 70 years and older, current smoking history, dry skin, low body mass index, urinary and fecal incontinence, physical restraints, malignancy, vasopressin prescription, and history of prior pressure injury development.
In the Southern Hemisphere, the Pole of Cold is currently located in Antarctica, at the Russian (formerly Soviet) Antarctic station Vostok at 78°28′S 106°48′E. On July 21, 1983, this station recorded a temperature of −89.2 °C (−128.6 °F). This is the lowest naturally occurring temperature ever recorded on Earth. Vostok station is located at the elevation of 3,488 m (11,444 ft) above sea level, far removed from the moderating influence of oceans (more than 1,000 km [620 mi] from the nearest sea coast), and high latitude that results in almost three months of civil polar night every year (early May to end of July), all combine to produce an environment where temperatures rarely rise above −25 °C (−13 °F) during summer and frequently fall below −70 °C (−94 °F) in winter. By comparison, the South Pole, due to its lower elevation, is, on average, 5 to 10 °C (9 to 18 °F) warmer than Vostok, and the lowest temperature ever recorded at the South Pole is −82.8 °C (−117 °F). It is generally thought that Vostok is not the coldest place in Antarctica, and there are locations (notably, Dome A) that are modestly colder on average. The now inactive Plateau Station, located on the central Antarctic plateau, recorded an average yearly temperature that was consistently lower than that of Vostok Station during the 37-month period that it was active in the late 1960s, with its average for the coldest month being several degrees lower than the same statistic for Vostok. Plateau Station never recorded a temperature that surpassed the record low set at Vostok.
Baiye, qianzhang, or gandoufu (百葉; 千張; 乾豆腐) is a very flat (about 2 mm thick) type of extra-firm tofu. It cannot be crumbled. The surface is filled with bulges arranged in a square grid from the muslin used to press it. It can be cut into long strings with a cross-section smaller than 2 mm × 2 mm and eaten in a way similar to gansi. It is also used to make：
The Vietnam National Games (Vietnamese: Đại hội Thể thao toàn quốc, lit. 'National Sports Games') is a major national multi-sport event normally held in Vietnam once every four years (previously once held every five years from 1985 to 1995), organised by the Sports Authority of Vietnam (Vietnamese: Cục Thể Dục thể thao Việt Nam, lit. 'Vietnam Department of Physical Education and Sports'). The inaugural Games took place in 1985 in Hanoi, and the most recent was held in 2022 in Quảng Ninh. Almost every sports delegations representing provinces, cities, ministries, and sectors that have participated in the Games throughout history have won at least one medal in every edition, except for four delegations: Hà Tuyên, Nam Hà, Nghĩa Bình và Thuận Hải, which have never won any medals; these were all former provinces that have now been dissolved, forming eight successor administrative units: Hà Giang and Tuyên Quang (separated from Hà Tuyên), Nam Định and Hà Nam (separated from Nam Hà), Quảng Ngãi and Bình Định (separated from Nghĩa Bình), Bình Thuận and Ninh Thuận (separated from Thuận Hải). After becoming independent, these provinces continued to send athletes to participate as separate sports delegations, and it was from this point that they began to achieve their first significant successes. The Games have been held in 5 provinces & cities: five times in Hanoi (1985, 1990, 1995, 2002, 2018), and once each in Đà Nẵng (2010), Nam Định (now Ninh Bình) (2014), Quảng Ninh (2022), and Ho Chi Minh City (2006).
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.